Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAlexandria University

About this trial

This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.

The study is comparing two oral medications for their effectiveness as a preventive treatment:

* Diosmin-Hesperidin (a flavonoid supplement). * Loratadine (a common anti-allergy medication).

The core question the study is trying to answer is:

* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine? * Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?

Eligibility criteria

Qualifiers

Adults 18 to 65 years old

Patients with or without bone pain associated with G-CSF administration.

Willingness to provide informed consent to participate in the study.

Disqualifiers

Patients with solid tumors.

Pregnant or breastfeeding women.

Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.

Patients with pre-existing bone disorders or receiving bone modifying agents

Trial design

Treatments tested in this trial

  • Loratadine
  • Diosmin-Hesperidin
  • Loratadine + Diosmin-Hesperidin

Treatment groups

88 Participants
are divided into 4 treatment groups

Sponsors and collaborators